VenatoRx Raises $42 Million Series B: Versant, Abingworth, Foresite Back Industry-Leading Antibiotics Developer

By WebmasterJuly 25, 2017November 1st, 2024No Comments

VenatoRx Raises $42 Million Series B: Versant, Abingworth, Foresite Back Industry-Leading Antibiotics Developer

Previous PostVenatoRx Receives $9.4 Million from CARB-X to Develop a New Class of Antibiotic to Combat Multi-Drug Resistant Bacteria
Next PostRelmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program